These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15099965)

  • 1. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer.
    Chiara S; Tognoni A; Pastrone I; Tomasello L; Brema F; Di Costanzo G; Folco U; Pronzato P;
    Gynecol Oncol; 2004 May; 93(2):474-8. PubMed ID: 15099965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
    Lorusso V; Gebbia V; Spada M; Guida M; Cassano G; Brunetti C; Germano D; Nettis G; Izzi G; Galetta D; Giampaglia M; Silvestris N; Colucci G
    Oncol Rep; 2005 Dec; 14(6):1547-51. PubMed ID: 16273254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 2000 Oct; 79(1):116-9. PubMed ID: 11006042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen.
    González-Martín A; Crespo C; García-López JL; Pedraza M; Garrido P; Lastra E; Moyano A
    Gynecol Oncol; 2002 Mar; 84(3):368-73. PubMed ID: 11855871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
    Stathopoulos GP; Malamos NA; Aravantinos G; Rigatos S; Christodoulou Ch; Stathopoulos J; Skarlos D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):123-8. PubMed ID: 17111119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
    Gordon AN; Asmar L; Messing MJ; Street DG; Pippitt CH; Bailey CL; Savage J; Young JA
    Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
    Schneider CP; Merkel U; Grübner U; Kath R; Höffken K; Hoffmann A
    J Cancer Res Clin Oncol; 2002 Jun; 128(6):313-8. PubMed ID: 12073049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer.
    Hanjani P; Nolte S; Shahin MS
    Gynecol Oncol; 2002 May; 85(2):278-84. PubMed ID: 11972388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
    Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
    Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
    Spannuth WA; Leath CA; Huh WK; Barnes MN; Davidson SA; Kilgore LC; Partridge EE; Austin JM; Alvarez RD
    Gynecol Oncol; 2007 Mar; 104(3):591-5. PubMed ID: 17045635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb RK; Lippmann L; Coleman RL; Mutch DG
    Gynecol Oncol; 2008 Dec; 111(3):467-73. PubMed ID: 18834619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study.
    Baur M; Fazeny-Doerner B; Hudec M; Sevelda P; Salzer H; Dittrich C
    Cancer Invest; 2006 Feb; 24(1):22-7. PubMed ID: 16466988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
    Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T
    Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
    Sood AK; Lush R; Geisler JP; Shahin MS; Sanders L; Sullivan D; Buller RE; Sorosky JI
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6080-5. PubMed ID: 15447993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.
    Sørensen P; Pfeiffer P; Bertelsen K
    Gynecol Oncol; 1995 Jan; 56(1):75-8. PubMed ID: 7821851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
    Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
    O'Malley DM; Azodi M; Makkenchery A; Tangir J; McAlpine J; Kelly M; Schwartz P; Rutherford T
    Gynecol Oncol; 2005 Aug; 98(2):242-8. PubMed ID: 15992916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.